+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

First-trimester biochemical screening for fetal chromosome abnormalities and neural tube defects

First-trimester biochemical screening for fetal chromosome abnormalities and neural tube defects

Prenatal Diagnosis 13(8): 681-689

Alpha-fetoprotein (AFP), unconjugated oestriol (UE3), intact human chorionic gonadotrophin (intHCG), and the free beta subunit of chorionic gonadotrophin (F beta HCG) were investigated in a series of 21 chromosomally abnormal and 14 open neural tube defect pregnancies ascertained from a series of 14,000 prospectively collected maternal serum samples at 6-14 weeks' gestation. In 16 cases of Down's syndrome, significant reductions were found for AFP (0.65 multiples of the normal median) and UE3 (0.67 MOM). IntHCG levels were unaltered (0.97 MOM) but a significant increase was found for F beta HCG (1.96 MOM). Significant correlations were found for AFP and UE3 in the controls and for intHCG and F beta HCG in both the control and the Down's syndrome pregnancies. In a group of five trisomy 18 pregnancies, median MOMs were for AFP 0.71, for UE3 0.34, for intHCG 0.27, and for F beta HCG 0.15. None of 13 pregnancies with open neural tube defects at 8-13 weeks gestation had elevated maternal serum AFP levels, whereas matched second-trimester samples from the same pregnancies at 16-18 weeks gestation all had significantly elevated AFP levels. Thus, biochemical screening for chromosome abnormalities may be practicable in the first trimester using free beta human chorionic gonadotrophin in combination with AFP and maternal age. However, a separate screening protocol using AFP at 15-18 weeks gestation would still be required for effective detection of neural tube defects.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 046099414

Download citation: RISBibTeXText

PMID: 8284287

DOI: 10.1002/pd.1970130804

Related references

First trimester screening for chromosome abnormalities and neural tube defects. American Journal of Human Genetics 51(4 Suppl. ): A251, 1992

Screening and diagnosis of fetal neural tube defects, abdominal wall defects and Down's syndrome. With special reference to biochemical and ultrasound screening in the second trimester of pregnancy and to early amniocentesis. Danish Medical Bulletin 48(3): 127-145, 2001

Maternal serum screening for neural tube defects and fetal chromosome abnormalities. Western Journal of Medicine 159(3): 312-317, 1993

The second trimester screening for fetal chromosomal aneuploidy and open neural tube defects. 2007

Second trimester maternal serum screening for fetal open neural tube defects and aneuploidy. Genetics in Medicine 6(6): 540-541, 2004

Is MSAFP still a useful test for detecting open neural tube defects and ventral wall defects in the era of first-trimester and early second-trimester fetal anatomical ultrasounds?. Fetal Diagnosis and Therapy 37(3): 206-210, 2015

Prenatal screening for neural tube defects and chromosome abnormalities: the complexities of program evaluation. Epidemiology 6(1): 1-4, 1995

Alpha-fetoprotein and free-beta chorionic gonadotropin as markers in biochemical second-trimester screening for Downs syndrome and neural tube defects. Clinical Chemistry & Laboratory Medicine 37(SPEC Suppl. ): S364, 1999

Biochemical screening of fetal aneuploidies and neural tube defects by "double-test" in Croatia: a 10 years' experience. Collegium Antropologicum 35(3): 957-962, 2011

Neural tube defects, chromosome abnormalities and multiple closure sites for the human neural tube. Clinical Dysmorphology 4(3): 202-207, 1995

Double-positive maternal serum screening results for Down syndrome and open neural tube defects: An indicator for fetal structural or chromosomal abnormalities and adverse obstetric outcomes. American Journal of Obstetrics & Gynecology 187(3): 758-763, 2002

First-trimester screening for neural tube defects using alpha-fetoprotein. Fetal Diagnosis and Therapy 31(2): 109-114, 2012

Maternal serum alpha fetoprotein screening for neural tube defects report of a combined study in germany and short overview on screening in populations with low birth prevalence of neural tube defects. Human Genetics 69(1): 47-61, 1985

EP06.06: The assessment of diagnosis of fetal neural tube defects by ultrasound in the first trimester. Ultrasound in Obstetrics & Gynecology 50: 285-285, 2017

Chromosome abnormalities in antenatally diagnosed neural tube defects. American Journal of Human Genetics 59(4 Suppl. ): A323, 1996